Phase II only: Percentage and characterization (if feasible based on patient number) of dabigatran initiators with contraindications (overall and per contraindication captured) [ Time Frame: up to 2 years ] [ Designated as safety issue: Yes ]

Phase II only: Percentage and characterization of dabigatran initiators with relevant comedications that should be used with caution [ Time Frame: up to 2 years ] [ Designated as safety issue: Yes ]

Phase II only: Percentage and characterization (if feasible based on patient number) of dabigatran initiators receiving 150 mg BID although 110 mg BID is recommended according to SmPC (e.g. patients > 80 years or patients with high bleeding risk) [ Time Frame: up to 2 years ] [ Designated as safety issue: Yes ]

Phase II only: Percentage and characterization (if feasible based on patient number) of dabigatran initiators without an interruption of dabigatran due to outcome events (e.g. major bleeds, major trauma), procedures. [ Time Frame: up to 2 years ] [ Designated as safety issue: Yes ]

In this part of the Registry Program patients with non-valvular atrial fibrillation (AF) at risk for stroke are enrolled to characterize the target population and to collect real world data on important outcome events. For administrative purposes the study is divided into two protocol numbers: 1160.129 for non-EU (European Union) and non-EEA (European Economic Area) countries, and 1160.136 for EU and EEA countries. The total number of patients enrolled in both protocols is estimated to be 48,000 patients, and all these patients will be included in the data analysis for study 1160.129.